Published online Jul 31, 2006.
https://doi.org/10.4111/kju.2006.47.7.786
Effects of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) on the Interleukin-6 Expression in the Prostate Cancer Cell Line PC-3
Abstract
Purpose
Interleukin-6 (IL-6) can stimulate a variety of tumors including prostatic carcinoma. Research has recently shown that IL-6 may act to stimulate the progression of prostatic cancer. IL-6 is elevated in the sera of patients with metastatic prostatic cancer and it has been shown to be a candidate marker of disease activity. To date, little work has been performed to characterize the nature of granulocyte macrophage colony-stimulating factor (GM-CSF) and the expression of IL-6. The aim of this study is to evaluate the effects of GM-CSF on the expression of IL-6 in PC-3 cells.
Materials and Methods
The bone-derived PC-3 cell line was used in this study. Reverse transcription polymerase chain reaction (RT-PCR) was performed to detect the GM-CSF and also the IL-6 mRNA expression. The IL-6 protein was measured by enzyme-linked immunosorbent assay (ELISA) after treatments with the hGM-CSF.
Results
hGM-CSF was expressed in the PC-3 cell line. Our data indicated that the IL-6 mRNA expression was not increased at 4, 8 and 12 hours by the hGM-CSF in comparison to the control group, but it was slightly increased at 24 and 48 hours. The expression of IL-6 protein was increased at 4, 8, 12, 24 and 48 hours after hGM-CSF treatment, in comparison with the control group.
Conclusions
The IL-6 mRNA expression was slightly increased by hGM-CSF at 24 and 48 hours in comparison to the control group. Yet the IL-6 protein expression increased before the IL-6 mRNA expression. Therefore, hGM-CSF may modulate the post-transcription pathway of the IL-6 expression in prostate carcinoma cells. Our data suggest that GM-CSF may have a possible IL-6 mediated pathophysiologic role in prostate cancer.
Fig. 1
hGM-CSF* expression in PC-3. *hGM-CSF: human granulocyte macrophage colony-stimulating factor.
Fig. 2
Time course of the IL-6mRNA expression in PC-3 cells. The PC-3 cells were treated with hGM-CSF for the indicated times. The IL-6mRNA expression is not increased at 4, 8 and 12 hours, but the IL-6mRNA expression is increased at 24 and 48 hours. *IL-6: interleukin-6, †GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
Fig. 3
The averages of the interleukin-6 (IL-6) concentrations (ng/ml) and their standard deviation for the incubation periods as determined by ELISA. The IL-6 protein expression is significantly increased at 4, 8, 12, 24 and 48 hours after hGM-CSF treatment compared with the control group. *: p<0.05.
Table 1
Primer sequences of the reverse transcription polymerase chain reaction (RT-PCR)
References
-
Korea Statistical Information System. National Statistical office. Republic of Korea.Available from: URL: http://kosis.nso.go.kr.
-
-
Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003;9:370–376.
-
-
Nicola NA. Hemopoietic growth factors and their interactions with specific receptors. J Cell Physiol 1987 Suppl 5:9–14.
-
-
Guillaume T, Sekhavat M, Rubinstein DB, Hamdan O, Symann ML. Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. Cancer Res 1993;53:3139–3144.
-
-
Rivas CI, Vera JC, Delgado-Lopez F, Heaney ML, Guaiquil VH, Zhang RH, et al. Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. Blood 1998;91:1037–1043.
-
-
Kim TH, Kim YS, Myung SC, Lee DH, Won EH, Lee SY. The prostaglandin E receptor agonists increase granulocyte macrophage colony-stimulating factor in prostate cancer cells. Korean J Urol 2004;45:1272–1278.
-
-
Rokhlin OW, Griebling TL, Karassina NV, Raines MA, Cohen MB. Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface. Anticancer Res 1996;16:557–563.
-
-
Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702–2706.
-
-
Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I. Expression of the interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res 1990;50:7786–7788.
-
-
Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141–146.
-
-
Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;139:2159–2165.
-
-
Charyulu VI, Lopez DM. Elevated GM-CSF levels in tumor bearing mice upregulate IL-6 production by B cells via a mechanism independent of TNF-α. Int J Oncol 2000;16:161–167.
-